BRAND NAME:
Scimox

GENERIC NAME:
Moxifloxacin 400mg (as hydrochloride)

THERAPEUTIC SEGMENT:
Broad spectrum quinolone antibiotic.

INDICATIONS:

• Acute Exacerbation of Chronic Bronchitis
• Community-acquired Pneumonia
• Acute Bacterial Sinusitis
• Uncomplicated Skin and Skin Structure Infection
• Complicated Skin and Skin Structure Infection
• Complicated Intra-abdominal Infection

BRIEF DESCRIPTION:
Moxifloxacin is a new 8-methoxyfluoroquinolone that has a wider antibacterial spectrum than earlier quinolones. Moxifloxacin exerts its bactericidal activity by binding to and inhibiting bacterial topoisomerases, (i.e. topoisomerase II (gyrase) and topoisomerase IV).

It provides good cover against Gram-positive organisms,’atypical’ pathogens and anaerobes, in addition to maintaining the excellent activity against Gram negative organisms of earlier agents in its class.

Moxifloxacin is rapidly and almost completely absorbed after oral administration, achieving levels within body tissues, particularly those of the respiratory tract, well above the minimum inhibitory concentration (MIC90) of the principal pathogens implicated in RTIs – Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Moxifloxacin is equally active against both penicillin- and macrolide-resistant strains of these organisms.

DOSAGE FORM:
Tablet 400mg 

PACK SIZE:
5’s